7th Cancer Cachexia Conference
|
7:00 am |
Registration and Morning coffee All plenary sessions are held in The Wolfson Hall, Qincentenary Building |
|
8:00 am |
Welcome and Introductory Remarks |
|
|
Session A: State-of-the-Knowledge: Clinical Fundamentals of Cancer Cachexia Chair: Tora Solheim, MD - Norwegian University of Science and Technology, NORWAY |
|
8:10 am |
Update on consensus definition of cancer cachexia |
8:40 am |
Endpoints in cachexic clinical trials - taking stock, moving forward |
9:10 am |
Cardiac wasting in advanced cancer & its therapeutic implications |
9:40 am |
Body composition and lung cancer-associated cachexia in TRACERx |
9:55 am |
Initial changes in weight, fatigue, and physical functioning during oxaliplatin-based chemotherapy in patients with colorectal and pancreatic cancer: A preliminary analysis from the PATTERN study (NCT05790538) |
10:10 am |
COFFEE BREAK offered by Almac Discovery |
Session B: Recent Clinical Trials and Trial Results Chair: Richard Skipworth, MBChB MD FRCS - University of Edinburgh, SCOTLAND |
|
10:30 am |
Ponsegromab as a potential therapy for cancer cachexia |
11:00 am |
Central relays in cancer cachexia |
11:30 am |
Clinical Update on Anamorelin: Efficacy and Safety Results from the SCALA Phase 3 Studies |
12:00 pm |
FORCE: Results from a randomized trial of resistance training in colon cancer patients undergoing chemotherapy |
12:15 pm |
A randomized phase II study of early nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study |
12:30 pm |
LUNCH BREAK - Cachexia Speed Networking |
|
|
Chair: Jose Garcia, MD, PhD - VA Puget Sound Health Care System, USA |
|
1:30 pm |
Developing a Cachexia Lexicon |
1:45 pm |
Patient-Provider-Caregiver Panel Panel: |
|
|
Chair: Barry Laird, MBChB MRCGP MD - University of Edinburgh, SCOTLAND |
|
3:00 pm |
History of cancer cachexia research in Glasgow |
3:25 pm |
Cachexia research - the Edinburgh perspective |
3:45 pm |
COFFEE BREAK offered by Almac Discovery |
|
|
Co-Chairs: |
|
4:00 pm |
Hepatic STAT3 signaling impairs ketogenesis and drives early pancreatic cancer cachexia |
4:15 pm |
Transcriptionally Diverse Myonuclei are Present Prior to Muscle Wasting in PDAC Cachexia |
4:30 pm |
Respiratory Muscle Pathology in Patients with Esophagogastric Adenocarcinoma |
4:45 pm |
Tumoral acidosis supports adipose tissue depletion by fostering adipose lipolysis |
5:00 pm |
Refractory cachexia causes an unexpected hypersensitivity to insulin |
5:15 pm | Deciphering the cachexia-inducing signature Roberta Sartori, PhD - University of Padova, ITALY |
|
|
5:30 pm |
Introduction from the Chair |
5:35 pm |
Towards a consensus on standards for rodent models of cancer cachexia |
5:55 pm |
The CCS Clinical Trials Advisory Board |
6:15 pm |
End of Scientific Program Day |
7:00 pm |
*SOCIAL EVENTS – Optional *Social events have limited capacity, and require pre-registration |
7:30 am |
7:45 am |
Registration and Morning Coffee |
|
|
||
8:25 am |
Introduction from the Chair |
|
8:30 am |
Leveraging our microbial world for our understanding of cachexia |
|
9:00 am |
The Role of Positron Emission Tomography in Understanding Cancer Cachexia |
|
9:30 am |
Identifying metabolic drivers of cancer cachexia with metabolomics and metabolic flux quantifications |
|
10:00 am |
Working Towards a Precision Medicine Framework in Cancer Cachexia: Learning from Patients |
|
10:30 am |
COFFEE BREAK offered by Nutricia |
|
|
||
Chair: Teresa A Zimmers, PhD - Oregon Health & Science University, USA |
||
10:45 am |
Pancreatic Cancer Cachexia |
|
11:15 am |
Heterogeneity of cachexia development in NSCLC |
|
11:45 am |
Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of treatment-naive patients with pancreatic cancer |
|
12:15 pm |
The relationship between tumour IL-6/JAK/STAT and NFKB pathway activation, the systemic inflammatory response; body composition and survival in patients with operable colon cancer |
|
12:30 pm |
Blocking the release of cancer cell-derived extracellular vesicles attenuates cancer-associated cachexia |
|
12:45 pm |
LUNCH BREAK |
|
1:45 pm |
Exhibit and Poster Viewing AOffered by Helsinn Healthcare SA |
|
2:45 pm |
Exhibit and Poster Viewing BOffered by Helsinn Healthcare SA |
|
3:30 pm |
COFFEE BREAK offered by Nutricia |
|
|
||
Chair: Erin Talbert, PhD - University of Iowa, USA |
||
4:00 pm |
Muscle-tumor crosstalk during cancer cachexia |
|
4:30 pm |
Host Murf1 deletion preserves muscle and slows pancreatic cancer progression |
|
5:00 pm |
Tumor-host cross talk: delineating the reciprocal contribution of muscle wasting to tumor progression |
|
5:15 pm |
BNIP3-dependent muscle atrophy in cancer cachexia promotes PDAC progression |
|
5:30 pm |
End of Scientific Program Day |
|
6:30 pm | *Festive Dinner | |
9:00 pm | *Cèilidh – a traditional Scottish party |
7:45 am |
Registration and Morning coffee All plenary sessions are in Wolson Hall, Qincentenary Buildling |
|||
|
||||
Chair: Fabio Penna, PhD - University of Torino, ITALY | ||||
8:15 am |
Gut microbiome alterations and metabolic disorders in acute myeloid leukemia |
|||
8:45 am |
Tumour-host interactions and metabolic dependencies during cachexia-like organ wasting in Drosophila melanogaster |
|||
9:15 am |
Inter- and intra-tissue crosstalk underlying cancer-associated cachexia |
|||
9:30 am |
Development of a peptide drug restoring AMPK and adipose tissue functionality in cancer cachexia |
|||
9:45 am |
The tumor-liver axis as a mediator of cancer-induced musculoskeletal wasting |
|||
10:00 am |
COFFEE BREAK offered by Abbott |
|||
|
||||
10:15 am |
Introduction of Kenneth C.H. Fearon Memorial Lecture |
|||
10:20 am |
How Different Environments Can Influence Our Understanding of Muscle Wasting in Cancer Cachexia |
|||
|
||||
Chair: Denis Guttridge, PhD - Medical University of South Carolina, USA | ||||
11:30 am |
Novel AI to characterise and discover undiagnosed and miscoded patients with cancer cachexia at scale in a privacy-preserving manner |
|||
11:35 am |
Utilizing age-appropriate models to decipher metabolic targets in cancer cachexia |
|||
11:40 am |
Genome and transcriptome signatures of cachexia in metastatic pancreatic ductal adenocarcinoma |
|||
11:45 am |
Muscle and adipose wasting despite disease control: unaddressed side effects of chemotherapy for advanced pancreatic cancer |
|||
11:50 am |
Multi-organ systems map of vascular reprogramming during cancer-cachexia |
|||
12:00 pm |
LUNCH BREAK |
|||
|
||||
Chair: Marilia Seelaender, PhD - University of São Paulo, BRAZIL | ||||
1:30 pm |
Relationships Between Cancer Cachexia, Elevated Drug Clearance, and Immune Checkpoint Inhibitor Response |
|||
2:00 pm |
IL-6 and adaptive metabolism in cancer cachexia |
|||
2:30 pm |
Using cachexia to augment prognosis estimation after chimeric antigen receptor T-cell therapy in a multi-site study |
|||
2:45 pm |
A Systemic View of Cancer Cachexia: Consequences of Altered Metabolic Networks |
|||
3:00 pm
|
IL-5 promotes pro-cachectic PMN-MDSC functions in cancer-associated cachexia |
|||
3:15 pm |
COFFEE BREAK offered by Abbott |
|||
|
||||
Chair: Imed Gallouzi, PhD - KAUST, SAUDI ARABIA | ||||
3:30 pm |
A novel target for tumor growth and muscle wasting |
|||
4:00 pm |
Long noncoding RNAs in the regeneration of aging muscle |
|||
4:30 pm |
Age-related effects creating a permissive environment for sarcopenia |
|||
5:00 pm |
Racial/ethnic heterogeneity in cancer cachexia |
|||
5:30 pm |
CaCaOdb: a comprehensive transcriptomic database for cancer cachexia research |
|||
5:45 pm |
Presentation of Awards Closing Remarks |
|||
6:30 pm |
End of Conference |
*Social events are optional, have limited capacity, and require pre-registration
Please view the video for information on these Conference initiatives.
See you in Edinburgh!